Skip to main content
Signal8

Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates

$INCYPress releaseApr 28, 2026, 7:00 AM ETRead the release

Incyte delivered a strong Q1 with total revenue of $1.27 billion, up 21% year-over-year, driven by 20% growth in net sales to $1.10 billion. The pipeline generated significant catalysts, including positive Phase 3 results for povorcitinib in nonsegmental vitiligo and the initiation of a pivotal Phase 3 study for INCB161734 in pancreatic cancer.

Key figures

Eps
1.47
Revenue
$1.27 billion
Drug Name
povorcitinib
Guidance
Total net sales $4.77 - $4.94 billion
Revenue Yoy
21%
Phase Of Trial
Phase 3

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    INCY: Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates — AI Analysis | Signal8